ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data
BioSpace
AstraZeneca is pushing its small molecule GLP-1 drug to Phase 3 development for weight control, diabetes and other cardiometabolic conditions despite the asset failing to best one from Structure Thera
pharminent
June 9, 2026 (Last updated: June 9, 2026)
BioSpace
AstraZeneca is pushing its small molecule GLP-1 drug to Phase 3 development for weight control, diabetes and other cardiometabolic conditions despite the asset failing to best one from Structure Thera
